Your compounded GLP-1 vial may show medication remaining — and may even carry longer instructions from your pharmacy — but FDA now recommends discarding multi-dose vials 28 days after the first puncture.

Here's what the updated guidance actually says and what it means for you.

What FDA Published

FDA updated its unapproved GLP-1 drug safety communication page with unusually specific instructions for compounded GLP-1 medications supplied in multi-dose vials.

The updated guidance states:

Discard the vial within 28 days after first use, even when medication remains.

Do not use it beyond 28 days even if the compounder's instructions permit longer use.

Use a new sterile needle and syringe for every dose.

Do not use injectable GLP-1 medication that arrived warm or with inadequate ice packs.

FDA's stated reason: contamination risk increases after 28 days.

Source: FDA, "FDA's Concerns About Unapproved GLP-1 Drugs Used for Weight Loss" — fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (content current as of September 1, 2026)

Three Terms That Are Different — And Why It Matters

This guidance highlights a distinction that most patients — and some providers — don't fully understand.

Expiration date: The date printed on the manufacturer's original sealed vial. Set by the manufacturer based on stability testing of the unopened product. Relevant before you open anything.

Beyond-use date (BUD): The date assigned by the compounding pharmacy, representing how long the compounded preparation remains stable and usable after it was prepared. This is what your pharmacy's label shows.

Post-puncture use period: How long a multi-dose vial remains safe to use after the seal has been broken and the first dose drawn. This is what FDA is now directly addressing — and saying 28 days is the limit, regardless of the BUD.

A vial might have a BUD of 90 days. That means the pharmacy determined the compound stays stable for 90 days after preparation. But FDA is now explicitly saying: once you puncture it and start drawing doses, 28 days is the contamination risk threshold — and you should discard it at that point whether or not medication remains.

These are related but distinct concepts. FDA is not saying compounded GLP-1s expire in 28 days. It's saying the risk of contamination in a punctured multi-dose vial rises meaningfully after 28 days.

What the Adverse Event Numbers Show

FDA also updated its adverse event count through May 31, 2026:

990 adverse event reports associated with compounded semaglutide
More than 730 adverse event reports associated with compounded tirzepatide

Two things FDA explicitly states about these numbers:

They do not prove causation. An adverse event report documents that someone experienced a health problem while using a product — not that the product caused the problem.

They are likely underreported. Most 503A compounding pharmacies are not federally required to submit adverse event reports to FDA. The actual number of incidents is probably higher than what's captured here.

Both caveats matter. The numbers are real. What they prove is limited.

What This Is — and What It Isn't

What this is:

An FDA safety communication — a public guidance document
A clearly published warning that increases clinical and liability risk for anyone dispensing compounded GLP-1 vials with longer use instructions
Applicable to all multi-dose vials of compounded semaglutide and tirzepatide

What this is not:

A final rule
A binding regulation
A recall
A change to the 503A or 503B bulks lists
A product-specific stability determination for any particular compound

FDA explicitly frames this as a general recommendation based on contamination risk from multi-dose sterile vials — not based on specific stability testing of any individual compounded product.

Not following a clearly published FDA contamination warning doesn't create legal liability in the same way that violating a final rule does. But the clinical and reputational risk of disregarding it is real.

What This Means Operationally

For anyone currently using compounded GLP-1 in a multi-dose vial:

Check your vial. When did you first puncture it? If it's been more than 28 days, FDA is now explicitly recommending you discard it even if medication remains.

Check your instructions. If your pharmacy or clinic gave you instructions suggesting the vial is safe for 60-90 days after first use, those instructions now conflict with FDA's published guidance.

A new needle and syringe for every dose. This is basic sterile technique and has always been the standard — FDA restates it because reuse is a documented contamination route.

Don't use vials that arrived warm. Cold chain failures are a real quality issue with compounded injectables. If a vial arrived at room temperature or was clearly not refrigerated, FDA recommends not using it.

For clinics, compounders, and practitioners:

Vial sizing matters now. If you're supplying vials intended for 60-90 days of use, FDA guidance creates a conflict with what you can reasonably instruct patients to do. Multi-month packages, larger vials, and pricing structures built around extended vial use all need review.

Patient instructions need updating. Any written materials telling patients the vial is good for longer than 28 days after puncture now conflict with FDA guidance.

Why This Keeps Coming Up

The compounded GLP-1 market exists because FDA-approved versions of these medications have faced significant access barriers — supply shortages, cost, prior authorization delays, and insurance coverage gaps.

A 2026 single-center survey of 261 adults who had a GLP-1 prescription and then a gap of more than 90 days found that among those facing prior authorization, 49.7% either waited more than seven days or were never approved. 32.4% of current users reported a gap of 14 days or longer.

People turn to compounded versions because they can't consistently access the approved ones. The quality and safety of those compounded products — including how vials are handled after puncture — matters enormously for people who have no other realistic option.

FDA's updated guidance doesn't solve the access problem. It does clarify the safety standard that should apply once access is obtained.

Tracking Your Protocol Through This

If you're using a compounded GLP-1 and are concerned about vial safety, consistency, or access gaps — having a clear record of your protocol matters more than most people realize.

When did you start? What dose? When did you have gaps? What happened to your body composition, energy, and biomarkers during those periods?

That timeline is what you and your doctor use to make decisions when access is interrupted or the landscape shifts.

PeptidesGPT tracks your protocol version by version — so whatever happens with your supply chain, you have the data.

→ peptidesgpt.com

Sources:

FDA: "FDA's Concerns About Unapproved GLP-1 Drugs Used for Weight Loss" — fda.gov (content current as of September 1, 2026)
Chen Y, et al. "Patient-Reported Continuity of GLP-1 Receptor Agonist Therapy." Obesity Science & Practice. 2026;12(5):e70189. PMID 42683049. DOI 10.1002/osp4.70189.

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical or legal advice. Always consult a licensed healthcare provider before making decisions about your health, medications, or protocol.